Patent: 8,211,429
✉ Email this page to a colleague
Summary for Patent: 8,211,429
| Title: | Neuropilin antagonists |
| Abstract: | Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications. |
| Inventor(s): | Watts; Ryan J. (San Mateo, CA), Wu; Yan (Foster City, CA) |
| Assignee: | Genetech, Inc. (South San Francisco, CA) |
| Application Number: | 13/173,890 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,211,429
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | 8,211,429 | 2031-06-30 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | June 30, 2006 | 8,211,429 | 2031-06-30 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | August 10, 2012 | 8,211,429 | 2031-06-30 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | October 13, 2016 | 8,211,429 | 2031-06-30 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | March 20, 2018 | 8,211,429 | 2031-06-30 |
| Genentech, Inc. | SUSVIMO | ranibizumab | Injection | 761197 | October 22, 2021 | 8,211,429 | 2031-06-30 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
